
A BioCentury analysis of ESMO first-in-human abstracts finds antibody-drug conjugates outnumbering every other modality, even as payload innovation lags behind target innovation. On the latest BioCentury This Week podcast, BioCentury's analysts discuss the findings and Representative Jake Auchincloss' Faster Clinical Trials Act, which would embed trials in routine care and expand the NIH's All of Us biobank. The analysts also discuss how U.S. investors are reacting to Treasury's proposed COIN...
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.

Ep. 397 - What the U.S. midterms mean for biopharma

Ep. 396 - China’s first-order innovation

Ep. 394 - Security concerns in U.S., China reshaping biotech

Ep. 393 - China trends; Roche, Merck KGaA deals; Arrowhead & tau
Free AI-powered recaps of BioCentury This Week and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.